NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise
Clinical and preclinical data supports the notion that ClC-1 inhibition is a novel and highly translational therapeutic approach to improve symptoms in myasthenia gravis and, potentially, other diseases with compromised neuromuscular transmission
NMD670, a skeletal muscle targeted ClC-1 inhibitor, is in clinical development for the treatment of patients with generalized myasthenia gravis, spinal muscular atrophy, and Charcot-Marie- Tooth disease